Phase 3 trial meets main efficacy endpoint, but disability progression stats cause concern.
Pharma begins early intervention trial after Cosentyx shows “disease modifying” properties
Guselkumab can also be used if older drug Stellara fails.
The FDA has accepted Celgene’s filing for enasidenib.
Evaluate predicts sales could approach $8bn if approved.
Success with ozanimod would justify $7.2 billion outlay for Receptos.
But drug will have boxed warning over suicidal ideation.